Date stringdate 2012-01-01 00:00:00 2023-12-31 00:00:00 | Stock_symbol stringlengths 1 5 | Article_title stringlengths 1 255 | Article stringlengths 1 342k |
|---|---|---|---|
2023-01-30 00:00:00+00:00 | ABBV | How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks | Here's an eye-opening statistic: older Americans are more afraid of running out of money than of death itself.
And unfortunately, even retirees who have built a nest egg have good reason to be concerned - with the traditional approaches to retirement planning, income may no longer cover expenses. That means retirees ar... |
2023-01-30 00:00:00+00:00 | ABBV | Why AbbVie is a Top Socially Responsible Dividend Stock (ABBV) | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 4.0% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of... |
2023-01-30 00:00:00+00:00 | ABBV | Down 14.5%, Is Pfizer Stock a Screaming Buy? | As the major U.S. stock indices fell into bear territory in 2022, big pharma stocks quickly became an oasis for nervous investors -- in many cases thanks to their largely recession-proof business models, reliable cash flows, and dependable quarterly dividends.
AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), Eli ... |
2023-01-30 00:00:00+00:00 | ABBV | Eli Lilly (LLY) Lymphoma Candidate Pirtobrutinib Gets FDA Nod | Eli Lilly and Company LLY announced that the FDA, under an accelerated approval pathway, approved BTK inhibitor, pirtobrutinib (100 mg & 50 mg tablets) for the treatment of relapsed or refractory mantle cell lymphoma (MCL), in adult patients. The drug will be marketed by the trade name of Jaypirca and can be administer... |
2023-01-28 00:00:00+00:00 | ABBV | 7 Dividend Stocks to Buy Now or You’ll Be Kicking Yourself Later | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
The recent rally in equities may be prying some cash off the sidelines. But if you’re investing in pure growth stocks and avoiding dividend stocks altogether, I’d urge caution.
No, I’m not talking about what the Federal Reserve will do with interest rates. ... |
2023-01-28 00:00:00+00:00 | ABBV | 2 of the Best Dividend Stocks to Own in 2023 | Investors don't yet know what to expect in 2023. The market may slowly stroll along the path to recovery. Or it could race ahead, with stock prices soaring. In either case, it's a good idea to add some dividend stocks to your portfolio. They'll offer you guaranteed income no matter what the market does.
But which playe... |
2023-01-26 00:00:00+00:00 | ABBV | Interesting ABBV Put And Call Options For March 10th | Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the March 10th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new March 10th contracts and identified one put and one call contract of particular interest.
The put contract... |
2023-01-25 00:00:00+00:00 | ABBV | Want Safety and Growth in 2023? Try These Dividend Stocks. | Last year was a tough one for most companies and investors. The three major indexes touched bear territory. And even the strongest of companies saw their share prices slip. Everyone is hoping 2023 will bring better days. History indicates this might happen. Still, to maximize your chances of winning this year and over ... |
2023-01-25 00:00:00+00:00 | ABBV | Is the Pain Over for Baudax Bio Investors after a 70% Spike? | Baudax Bio (NASDAQ: BXRX) shares spiked as much as 70% on its announcement of positive interim phase 2 clinical trials for its pain medicine BX1000. While the interim positive outcome is based on a 20-patient group, it expects to complete the phase 2 trial with 80 patients by the end of the first quarter of 2023.
The d... |
2023-01-25 00:00:00+00:00 | ABBV | 3 Reasons to Buy AbbVie and 2 Reasons Not to Buy | 2023 is expected to be an important year for AbbVie (NYSE: ABBV). The pharmaceutical company is facing its first biosimilar competition in the United States. It's big news because it involves AbbVie's monoclonal antibody blockbuster therapy, Humira, which is on track to generate a second consecutive year of $20 billion... |
2023-01-24 00:00:00+00:00 | ABBV | Sum Up The Parts: USMV Could Be Worth $80 | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares MSCI USA Min Vol Factor... |
2023-01-23 00:00:00+00:00 | ABBV | AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know | AbbVie (ABBV) closed the most recent trading day at $148.55, moving -0.7% from the previous trading session. This change lagged the S&P 500's daily gain of 1.19%. At the same time, the Dow added 0.76%, and the tech-heavy Nasdaq gained 0.29%.
Heading into today, shares of the drugmaker had lost 8.28% over the past month... |
2023-01-23 00:00:00+00:00 | ABBV | AbbVie Enters Oversold Territory | The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive. AbbVie Inc (Symbol: ABBV) presently has an... |
2023-01-23 00:00:00+00:00 | ABBV | AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know | AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Over the past month, shares of this drugmaker have returned -8.3%, compared to the Zacks S&P 500 composite's +4.1% change. Dur... |
2023-01-22 00:00:00+00:00 | ABBV | AbbVie Is Set to Lose on Its Biggest Blockbuster. Here's Why You Shouldn't Worry. | AbbVie (NYSE: ABBV) boasts a portfolio of drugs across immunology, neuroscience, aesthetics, oncology, and eye care. Yet investors' focus lately has been on the fate of one particular product: the immunology drug Humira. That's because it's set to face competition in the U.S. as of this month.
Why is this such a proble... |
2023-01-20 00:00:00+00:00 | ABBV | Noteworthy Friday Option Activity: IBM, ATVI, ABBV | Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in International Business Machines Corp (Symbol: IBM), where a total volume of 89,115 contracts has been traded thus far today, a contract volume which is representative of approximately 8.9 million underlying ... |
2023-01-19 00:00:00+00:00 | ABBV | ABBV Crosses Above 4% Yield Territory | Looking at the universe of stocks we cover at Dividend Channel, in trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 4% mark based on its quarterly dividend (annualized to $5.92), with the stock changing hands as low as $147.33 on the day. Dividends are particularly important for investor... |
2023-01-19 00:00:00+00:00 | ABBV | 3 Unstoppable Stocks to Keep Buying in 2023 | Last year's market wasn't gloomy for every company. Investors bought certain stocks hand over fist. In most cases, these particular companies offered investors a solid reason to be optimistic about their future. And that's why they were able to defy the bear market.
I can easily think of three examples in the healthcar... |
2023-01-18 00:00:00+00:00 | ABBV | AbbVie Breaks Below 200-Day Moving Average - Notable for ABBV | In trading on Wednesday, shares of AbbVie Inc (Symbol: ABBV) crossed below their 200 day moving average of $150.37, changing hands as low as $149.09 per share. AbbVie Inc shares are currently trading off about 2.4% on the day. The chart below shows the one year performance of ABBV shares, versus its 200 day moving aver... |
2023-01-18 00:00:00+00:00 | ABBV | 7 Biotech Stocks That Will Make You Rich in 10 Years | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
If you have the patience to go through wild undulations, then you may be a candidate for biotech stocks that will make you rich in 10 years. Even among the most established biotechnology firms, they’re seemingly one news item away from disaster. Further, th... |
2023-01-18 00:00:00+00:00 | ABBV | 2 Cheap Growth Stocks That Can Set You Up for Life | Many would-be growth stocks out there are trading at valuations that aren't nearly as high as they were just a year or two ago. That suggests there are some deals out there for investors who know what to look for. Even if growth stocks don't fully recover this year, buying shares of growing businesses and holding them ... |
2023-01-18 00:00:00+00:00 | ABBV | Pick Either Johnson & Johnson Stock Or Its Peer – Both May Offer Similar Returns | We believe that pharmaceutical giants Johnson & Johnson stock (NYSE: JNJ) and Merck stock (NYSE: MRK) will likely offer similar returns over the next three years. Both companies are trading at a similar valuation of around 5.0x trailing revenues. If we look at stock returns, Merck, with a stellar 37% rise in the last ... |
2023-01-17 00:00:00+00:00 | ABBV | With Competition on the Rise, Is AbbVie's Dividend Safe? | The moment AbbVie's (NYSE: ABBV) shareholders have been dreading for years is finally coming. In late January, the company will start facing generic competition in the U.S. for its best-selling product, immunology drug Humira. Humira has been AbbVie's key asset since it became a stand-alone company in 2013.
The pharma ... |
2023-01-17 00:00:00+00:00 | ABBV | Could This FDA Approval Boost AbbVie's Stock? | On Dec. 16, the U.S. Food and Drug Administration (FDA) gave AbbVie's (NYSE: ABBV) Vraylar the go-ahead as an adjunctive (add-on) treatment for patients with major depressive disorder (MDD).
What was the clinical data behind the FDA's decision to award Vraylar with its fourth indication? And what could this news mean f... |
2023-01-17 00:00:00+00:00 | ABBV | AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know | AbbVie (ABBV) closed at $152.83 in the latest trading session, marking a -0.5% move from the prior day. This change lagged the S&P 500's 0.2% loss on the day. At the same time, the Dow lost 1.14%, and the tech-heavy Nasdaq gained 1.39%.
Heading into today, shares of the drugmaker had lost 4.89% over the past month, lag... |
2023-01-17 00:00:00+00:00 | ABBV | This Monumental Breakthrough Could Turn the World Upside Down -- and Make Some Investors Filthy Rich | You might have heard the stories about Ponce de Leon's search for the fountain of youth. As it turns out, there's no evidence that the Spanish explorer actually embarked on such a search. The stories appear to be as mythical as the fountain of youth itself.
But the idea of restoring youth could be about to move from my... |
2023-01-17 00:00:00+00:00 | ABBV | Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)? | Launched on 06/23/2005, the Invesco Dynamic Pharmaceuticals ETF (PJP) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Pharma segment of the equity market.
An increasingly popular option among retail and institutional investors, passively managed ETFs offer low costs,... |
2023-01-17 00:00:00+00:00 | ABBV | 5 Dividend Aristocrats Where Analysts See Capital Gains | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention — and furthermore, "tracking" funds that follow ... |
2023-01-16 00:00:00+00:00 | ABBV | Pick Either Merck Stock Or Its Peer – Both May Offer Similar Returns | We believe that pharmaceutical giants Merck stock (NYSE: MRK) and Pfizer stock (NYSE: PFE) will likely offer similar returns over the next three years. Although Merck is trading at a comparatively higher valuation of 4.9x trailing revenues vs.2.9x for Pfizer, this valuation gap can be attributed to Merck’s lower financ... |
2023-01-16 00:00:00+00:00 | ABBV | BioMed X Extends Research Collaboration With AbbVie On Immunology And Tissue Engineering | (RTTNews) - BioMed X, an independent German biomedical research institute, said that it has extended its ongoing research collaboration with AbbVie (ABBV). This marks the launch of the first BioMed X Institute in the US, to be located in New Haven, Connecticut.
BioMed X noted that the new US-based research collaboratio... |
2023-01-16 00:00:00+00:00 | ABBV | 3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income | Here's an eye-opening statistic: older Americans are more afraid of running out of money than of death itself.
And older Americans have legitimate reasons for this worry, even if they have dutifully saved for their golden years. That's because the traditional ways people manage retirement may no longer provide enough i... |
2023-01-16 00:00:00+00:00 | ABBV | 5 Dividend Kings I Bought for My Portfolio | In periods of rising inflation and slowing economic growth, one constant investors can count on is the reliability of dividend stocks to see them through.
The asset managers at Hartford Funds looked at the performance of the benchmark S&P 500 going all the way back to 1930 and found that dividends contributed 40% to th... |
2023-01-16 00:00:00+00:00 | ABBV | Should First Trust Morningstar Dividend Leaders ETF (FDL) Be on Your Investing Radar? | Looking for broad exposure to the Large Cap Value segment of the US equity market? You should consider the First Trust Morningstar Dividend Leaders ETF (FDL), a passively managed exchange traded fund launched on 03/09/2006.
The fund is sponsored by First Trust Advisors. It has amassed assets over $5.04 billion, making ... |
2023-01-16 00:00:00+00:00 | ABBV | AbbVie, Eli Lilly exit UK drug pricing agreement | Adds details, background
Jan 16 (Reuters) - Pharmaceutical companies AbbVie ABBV.N and Eli Lilly LLY.N have withdrawn from Britain's voluntary medicines pricing agreement, an industry body said on Monday.
Companies are increasingly arguing that it is no longer possible to justify the UK's "voluntary scheme" to global b... |
2023-01-13 00:00:00+00:00 | ABBV | Want to Get Richer? 3 Best Stocks to Buy Now and Hold Forever | Some people chase significant, fast returns -- the get-rich-quick approach. But in reality, the steady effects of long-term compounding usually create life-changing wealth. Successful investing can be as simple as owning stocks of high-quality businesses that have grown consistently for many years.
Healthcare is a supe... |
2023-01-13 00:00:00+00:00 | ABBV | FOCUS-Drug companies favor biotech meds over pills, citing new U.S. law | By Deena Beasley
San Francisco, Jan 13 (Reuters) - Drugmakers are prioritizing complex biotech medicines over treatments that can be given as pills because recent U.S. legislation gives biologics a longer runway before becoming subject to government price limits, top industry executives said this week.
The Inflation Re... |
2023-01-12 00:00:00+00:00 | ABBV | ABBV March 3rd Options Begin Trading | Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the March 3rd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new March 3rd contracts and identified one put and one call contract of particular interest.
The put contract a... |
2023-01-12 00:00:00+00:00 | ABBV | Zacks Market Edge Highlights: EXAS, ZM, TSLA, ABBV, ZOM | For Immediate Release
Chicago, IL – January 12, 2023 – Zacks Market Edge is a podcast hosted weekly by Zacks Stock Strategist Tracey Ryniec. Every week, Tracey will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life. To listen to the podcast, click here:
h... |
2023-01-12 00:00:00+00:00 | ABBV | Notable Thursday Option Activity: IAC, ABBV, RILY | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Iac Inc (Symbol: IAC), where a total volume of 11,137 contracts has been traded thus far today, a contract volume which is representative of approximately 1.1 million underlying shares (given that every... |
2023-01-11 00:00:00+00:00 | ABBV | 1 Hot Growth Stock to Buy Now, and 1 to Avoid | Discerning between popular growth stocks that have room to run and those that will leave your portfolio in the red isn't an easy task, especially for companies in the biopharma sector. Picking the businesses that have the right mix of reliable earnings and catalysts for growth is key, but it takes more than a drug appr... |
2023-01-11 00:00:00+00:00 | ABBV | The Stocks Behind 2022's Popular ETFs | (0:45) - Breaking Down Fund Flows For 2022: Should You Be Buying Back Into Cathie Wood?
(5:15) - What Is Cathie Wood Currently Buying?
(14:05) - Income ETFs On The Rise: Should You Be Adding Exposure To Your Portfolio?
(22:50) - Will The Energy Sector Continue To Outperform?
(32:30) - Episode Roundup: ARKK, SCHD, JEPI,... |
2023-01-11 00:00:00+00:00 | ABBV | 3 Supercharged Dividend Stocks to Buy If There's a Stock Market Sell-Off | Choosing solid dividend stocks can be tricky. Buying a stock with a really high dividend yield is tempting, but many stocks with high dividends got that way because their share prices have plummeted. Often there's a genuine reason for declining shares, such as declining revenue or earnings.
Many stocks with high yields... |
2023-01-10 00:00:00+00:00 | ABBV | AbbVie, Anima Biotech Collaborate To Develop MRNA Modulators In Oncology, Immunology Targets | (RTTNews) - AbbVie Inc. (ABBV), and Anima Biotech (Anima) Tuesday announced a collaboration in mRNA biology modulators for three targets across Oncology and Immunology. As per the agreement, Anima will receive an upfront payment of $42 million with the potential for further milestones and royalties and up to $540 milli... |
2023-01-10 00:00:00+00:00 | ABBV | AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know | AbbVie (ABBV) closed the most recent trading day at $159.64, moving -1.25% from the previous trading session. This move lagged the S&P 500's daily gain of 0.7%. Elsewhere, the Dow gained 0.56%, while the tech-heavy Nasdaq added 7.5%.
Heading into today, shares of the drugmaker had lost 2.21% over the past month, laggin... |
2023-01-10 00:00:00+00:00 | ABBV | 3 Passive Income Stocks That Are Screaming Buys in January | After the bear market of 2022 slammed the share prices of most companies, now is a particularly opportune time to identify passive income stocks while they're cheap. There's no time like the present to build the foundations for tomorrow's wealth -- especially when it comes to stocks you could buy and hold for decades.
... |
2023-01-10 00:00:00+00:00 | ABBV | Ex-Dividend Reminder: Buckle, Foot Locker and AbbVie | Looking at the universe of stocks we cover at Dividend Channel, on 1/12/23, Buckle, Inc. (Symbol: BKE), Foot Locker, Inc. (Symbol: FL), and AbbVie Inc (Symbol: ABBV) will all trade ex-dividend for their respective upcoming dividends. Buckle, Inc. will pay its quarterly dividend of $0.35 on 1/27/23, Foot Locker, Inc. wi... |
2023-01-10 00:00:00+00:00 | ABBV | AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know | AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Shares of this drugmaker have returned -2.2% over the past month versus the Zacks S&P 500 composite's -0.9% chan... |
2023-01-10 00:00:00+00:00 | ABBV | Should Investors Worry About AbbVie's Dividend? | There's not much point in buying a passive-income stock like AbbVie (NYSE: ABBV) if it's going to fail to deliver its quarterly dividend into your account. Even reliable companies can sometimes run into problems that require them to level off or even slash their payment.
As it turns out, there is indeed a risk that wit... |
2023-01-10 00:00:00+00:00 | ABBV | Abbvie raises sales outlook of two new drugs to more than $17.5 bln in 2025 | Adds background
Jan 10 (Reuters) - AbbVie Inc ABBV.N on Tuesday raised its 2025 sales forecast of its newer immunology drugs Skyrizi and Rinvoq to more than $17.5 billion as it hopes to replace the loss of revenue from its blockbuster rheumatoid arthritis drug Humira.
The company's previous sales outlook for Skyrizi an... |
2023-01-09 00:00:00+00:00 | ABBV | AbbVie's Qulipta Approved In Canada For Preventive Treatment Of Episodic Migraine In Adults | (RTTNews) - AbbVie (ABBV) said that Health Canada has approved Qulipta (atogepant) for the prevention of episodic migraine (less than 15 migraine days per month) in adults.
The approval is supported by data from a robust clinical program evaluating the efficacy, safety and tolerability of Qulipta in nearly 2,000 patien... |
2023-01-09 00:00:00+00:00 | ABBV | Top Dividend Stocks To Invest In 2023? 3 For Your List | A dividend stock is a type of stock that pays out a portion of the company’s profits to shareholders in the form of dividends. These payments are generally paid on a regular basis. This can include quarterly or annually. While dividends are typically paid in cash. Although they can also be paid in the form of additiona... |
2023-01-08 00:00:00+00:00 | ABBV | The 7 Best Dividend Stocks to Buy for Your Grandkids in 2023 | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
If you’re looking for some of the best dividend stocks for grandkids, now is the time to buy. After all, 2022 was an absolute disaster.
Whatever could have gone wrong went wrong. For many of us, 2022 became the year to forget. All thanks to sky-high inflati... |
2023-01-07 00:00:00+00:00 | ABBV | 3 No-Brainer Dividend Stocks to Buy in 2023 | Too many choices can lead to analysis paralysis. Consider that there are over 4,300 dividend stocks that trade on the major U.S. stock exchanges. It would be nice to whittle the list down to a handful.
With this in mind, we asked three Motley Fool contributors to pick no-brainer dividend stocks to buy in 2023. Here's w... |
2023-01-06 00:00:00+00:00 | ABBV | CytomX (CTMX) Up 55% on Strategic Partnership With Moderna | Shares of CytomX Therapeutics CTMX were up 55.3% in after-market trading on Jan 5 after management announced its collaboration agreement with Moderna MRNA to create investigational mRNA-based conditionally activated therapies.
The collaboration intends to combine Moderna's mRNA technology with CytomX's Probody Platform... |
2023-01-06 00:00:00+00:00 | ABBV | AbbVie, Immunome Collaborate To Discover Multiple Novel Oncology Targets | (RTTNews) - AbbVie (ABBV) and Immunome Inc. (IMNM) have collaborated to discover up to 10 novel antibody-target pairs arising from three specified tumor types using Immunome's Discovery Engine, the companies said in a statement.
As per the terms of the deal, Immunome will grant AbbVie the option to purchase worldwide r... |
2023-01-05 00:00:00+00:00 | ABBV | Noteworthy Thursday Option Activity: C, FDX, ABBV | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Citigroup Inc (Symbol: C), where a total of 135,279 contracts have traded so far, representing approximately 13.5 million underlying shares. That amounts to about 73.2% of C's average daily trading volume over the pa... |
2023-01-05 00:00:00+00:00 | ABBV | February 24th Options Now Available For AbbVie (ABBV) | Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the February 24th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new February 24th contracts and identified one put and one call contract of particular interest.
The put co... |
2023-01-05 00:00:00+00:00 | ABBV | HDV, VZ, ABBV, PFE: ETF Inflow Alert | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core High Dividend ETF (Symbol: HDV) where we have detected an approximate $511.7 million dollar inflow -- that's a 4.0% increase week over week in outstanding units (from 121,050,00... |
2023-01-05 00:00:00+00:00 | ABBV | ABBV Crosses Above Average Analyst Target | In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $162.53, changing hands for $163.69/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a... |
2023-01-04 00:00:00+00:00 | ABBV | These 2 Cheap Dividend Stocks Yield More Than 3% -- and They Beat the Market Last Year | It's OK to be greedy as an investor and want more than just a good dividend yield or solid growth. Some stocks actually offer both benefits, such as AbbVie (NYSE: ABBV) and ExxonMobil (NYSE: XOM). Plus, both stocks beat the market last year and yet are still trading cheaply. Here's why it may not be too late to invest ... |
2023-01-04 00:00:00+00:00 | ABBV | 1 Smart Trick That'll Make You a Better Investor Instantly | You need every edge you can get to succeed in investing, and sometimes it's the simplest tricks that get the most mileage.
So here's one incredibly smart trick that you definitely need to know: Don't look at the price of a stock before buying it. Price simply doesn't matter, whether it's a penny stock or something pric... |
2023-01-04 00:00:00+00:00 | ABBV | 20 Recession-Proof Stocks to Buy Now for 2023 | Today, I cover the 20 best recession-proof stocks to buy now for 2023. I discuss the industries and sectors that historically outperform during recessions, as well as 20 stock picks for you to explore.
*Stock prices used in the below video were during the trading day of Jan. 3, 2023. The video was published on Jan. 3, ... |
2023-01-04 00:00:00+00:00 | ABBV | 3 Outstanding Dividend Growth Stocks to Buy for 2023 | Would you like to know the worst-kept secret on Wall Street? Stocks with dividends that grow outperform stocks that don't pay dividends by a mile.
It stands to reason that companies committed to returning profits to shareholders outperform companies that don't. That said, the differences are probably more striking than... |
2023-01-03 00:00:00+00:00 | ABBV | AbbVie (ABBV) Gains As Market Dips: What You Should Know | AbbVie (ABBV) closed the most recent trading day at $162.38, moving +0.48% from the previous trading session. This move outpaced the S&P 500's daily loss of 0.4%. At the same time, the Dow lost 0.03%, and the tech-heavy Nasdaq lost 4.72%.
Coming into today, shares of the drugmaker had lost 1.42% in the past month. In t... |
2023-01-03 00:00:00+00:00 | ABBV | Beat the Dow Jones With This Unstoppable Dividend Stock | The iconic Dow Jones needs no introduction to those fully immersed in the investing world. It is composed of 30 leading companies in the U.S. and stands as one of the country's oldest and most popular stock market indexes. Like other major U.S. indexes, it has delivered solid returns over the long run, so perhaps inves... |
2023-01-03 00:00:00+00:00 | ABBV | 23 Top Dividend Stocks to Buy and Hold in 2023 | No one knows for sure what the new year will bring for investors. However, it's a good bet that quite a few solid companies will continue paying dividends quarter after quarter.
Some of them could also have significant upside potential over the next 12 months. Here are 23 top dividend stocks to buy and hold in 2023.
En... |
2023-01-02 00:00:00+00:00 | ABBV | The 10 Best Stocks to Buy in January 2023 | Today, I tell you the 10 best stocks to buy in January 2023, which I believe have significant upside for long-term investors. I provide a blend of stocks, from hypergrowth stocks to mature growth stocks and dividend stocks.
*Stock prices used in the below video were during the trading day of Dec. 30, 2022. The video wa... |
2022-12-31 00:00:00+00:00 | ABBV | 3 Dividend Stocks to Buy Hand Over Fist in 2023 | Dividend stocks shine in times like these. They pay investors to wait until market conditions improve, and they often deliver solid returns even when the market flounders.
We asked three Motley Fool contributors to identify dividend stocks they would buy hand over fist in 2023. Here's why they chose AbbVie (NYSE: ABBV)... |
2022-12-31 00:00:00+00:00 | ABBV | 3 Best Value Stocks to Buy Before 2023 | Astute students of the market probably know growth stocks have outpaced value stocks for the better part of the past 14 years. Although the overused axiom explains that "past performance is no guarantee of future results," this persistent outperformance certainly bolsters the bullish case for growth-oriented names.
How... |
2022-12-30 00:00:00+00:00 | ABBV | 2 "Safe" Stocks That Are Anything But | Safety in investing is often in the eye of the beholder, but not all that glitters is gold. Some stocks appear to be safe on the basis of the company's conservative business model or its large scale, only to leave investors exposed to brutal losses when financial results are worse than anticipated.
Avoiding buying thes... |
2022-12-29 00:00:00+00:00 | ABBV | Pfizer (PFE) Pentavalent Meningitis Jab BLA Gets FDA Acceptance | Pfizer PFE announced that the FDA has accepted the biologics license application (BLA) seeking approval of its pentavalent meningococcal vaccine candidate (MenABCWY).
The BLA seeks approval of MenABCWY for adolescents and young adults, 10-25 years of age, for the prevention of meningococcal disease caused by five menin... |
2022-12-29 00:00:00+00:00 | ABBV | 3 High-Yield Dividend Stocks to Supercharge Your Passive Income Portfolio | After more than a decade of near-zero interest rates, income investors are faced with a dilemma they haven't had to deal with for a long time. Right now, the average dividend-paying stock in the S&P 500 index offers a 1.7% yield. That's less than half the return you can receive risk-free on cash held in a savings accou... |
2022-12-28 00:00:00+00:00 | ABBV | The Zacks Analyst Blog Highlights AbbVie, PepsiCo, Oracle, HSBC Holdings and The Progressive | For Immediate Release
Chicago, IL – December 28, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AbbVie Inc. ABBV, PepsiCo... |
2022-12-27 00:00:00+00:00 | ABBV | AbbVie (ABBV) Stock Moves -0.07%: What You Should Know | In the latest trading session, AbbVie (ABBV) closed at $162.99, marking a -0.07% move from the previous day. This change was narrower than the S&P 500's 0.41% loss on the day. Meanwhile, the Dow gained 0.11%, and the Nasdaq, a tech-heavy index, lost 6.67%.
Coming into today, shares of the drugmaker had gained 2.95% in ... |
2022-12-27 00:00:00+00:00 | ABBV | 3 Dividend Kings Nicely Suited for Income Investors | Few things delight investors more than consistent, dependable dividend payouts.
After all, who doesn't enjoy being compensated for their investments?
Dividends were a valuable commodity for investors in 2022, helping to cushion the impact of drawdowns in other positions.
Dividend Aristocrats, companies that have increa... |
2022-12-27 00:00:00+00:00 | ABBV | Top Analyst Reports for AbbVie, PepsiCo & Oracle | Tuesday, December 27, 2022
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), PepsiCo, Inc. (PEP) and Oracle Corporation (ORCL). These research reports have been hand-picked from the roug... |
2022-12-24 00:00:00+00:00 | ABBV | 2 Healthcare Stocks You Can Buy and Hold for the Next Decade | It's a scary time to be an investor, with the markets languishing and the threat of additional interest rate hikes next year weighing on stock prices. In this environment, it is important to control risk and one way to do that is by investing in quality healthcare companies with consistent, sustainable dividends.
Cardi... |
2022-12-23 00:00:00+00:00 | ABBV | Roche's (RHHBY) Lunsumio Gets FDA Nod for Follicular Lymphoma | Roche RHHBY announced that the FDA approved intravenously-administered Lunsumio (mosunetuzumab) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) who have been treated with two or more lines of systemic therapy. Lunsumio has been approved by the regulatory agency under the a... |
2022-12-23 00:00:00+00:00 | ABBV | If You Invested $25,000 in AbbVie In 2020, This Is How Much You Would Have Today | AbbVie (NYSE: ABBV) is a top healthcare company that's worth nearly $290 billion. It has a diverse business that generates revenue from many different therapeutic areas. Its bread and butter is the immunology drug Humira, which has already brought in a whopping $15.7 billion in revenue through the first nine months of ... |
2022-12-21 00:00:00+00:00 | ABBV | Here's Why the Bear Market Could End in 2023 | The S&P 500 has dropped more than 19% this year, and many growth stocks have suffered even more severe declines along the way. Inflation and concerns about the economy have led investors to dump investments, even quality ones, out of fear that things will get worse.
But as bad as things are and with inflation still a p... |
2022-12-21 00:00:00+00:00 | ABBV | This Unstoppable Growth Stock Is Nearing a Once-In-a-Decade Buying Opportunity | Even the most intrepid growth stocks experience doldrums, and such periods can be a great time to start an investment. If you can predict slower patches in advance, you'll be positioned even better, and that's why it may be worth considering an investment in AbbVie (NYSE: ABBV) stock in the coming months.
The pharmaceu... |
2022-12-21 00:00:00+00:00 | ABBV | 2 Mammoth Stocks With Dividends to Buy Before 2022 Ends | There has been a lot of talk about a possible recession next year, when it might come, about how hard it might be, etc. Two healthcare stocks that are likely to thrive in such an environment include Cigna (NYSE: CI) and Johnson & Johnson (NYSE: JNJ).
The two companies have a big international reach and varied revenue s... |
2022-12-21 00:00:00+00:00 | ABBV | Top 15 Investing Tips for Beginners in 2023 and Beyond | Today, I share my top 15 investing tips for beginners in 2023 and beyond to help you be a successful long-term investor. I discuss growth stock investing, ETF investing, dividend growth stock investing, speculative stocks, the psychology of money, how to build a portfolio, and more.
*Stock prices used in the below vide... |
2022-12-20 00:00:00+00:00 | ABBV | 2 Exceptional Dividend Growth Stocks to Buy Now | This is kind of a strange time to be a passive income investor. After more than a decade of ultra-low interest rates, you can suddenly receive a risk-free 3.5% interest rate on your totally liquid savings account deposits. That's a little more than twice as much as the yield you'd receive from the average dividend-payi... |
2022-12-19 00:00:00+00:00 | ABBV | Validea's Top Five Healthcare Stocks Based On John Neff - 12/19/2022 | The following are the top rated Healthcare stocks according to Validea's Low PE Investor model based on the published strategy of John Neff. This strategy looks for firms with persistent earnings growth that trade at a discount relative to their earnings growth and dividend yield.
ENSIGN GROUP INC (ENSG) is a mid-cap g... |
2022-12-19 00:00:00+00:00 | ABBV | AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know | AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Over the past month, shares of this drugmaker have returned +3.6%, compared to the Zacks S&P 500 composite's -2.... |
2022-12-19 00:00:00+00:00 | ABBV | AbbVie (ABBV) Vraylar Gets FDA Nod for Major Depressive Disorder | AbbVie ABBV announced that the FDA has approved Vraylar (cariprazine) for the adjunctive treatment of patients with major depressive disorder (MDD).
Vraylar is presently approved for treating schizophrenia, the acute treatment of manic or mixed episodes associated with bipolar I disorder and depressive episodes associa... |
2022-12-18 00:00:00+00:00 | ABBV | The 7 Hottest Biotech Stocks to Own in 2023 and Beyond | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Some of the hottest biotech stocks are safe and recession-proof. After all, we can’t stop people from aging – at least, not yet. We can’t stop people from seeking treatments for a myriad of issues. Plus, there’s growing demand for innovation in gene therapi... |
2022-12-17 00:00:00+00:00 | ABBV | 6 Stocks Warren Buffett Completely Exited in 2022 | When Warren Buffett, one of the greatest investors of all time, makes a move, the market listens. His company Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) maintains an equities portfolio worth roughly $337 billion, and investors, through regulatory filings, can see what stocks Berkshire is buying and selling every thr... |
2022-12-16 00:00:00+00:00 | ABBV | 3 Supercharged Dividend Stocks to Buy If There's a Stock Market Sell-Off | The market has dished plenty of ups and downs to investors over the past year, and there's no telling exactly when the volatility will end. The good news is, as a long-term investor, you don't need to make your investment decisions around the whims of the market. Rather, as you focus your capital on quality companies w... |
2022-12-16 00:00:00+00:00 | ABBV | Time to Buy Eli Lilly (LLY) and AbbVie (ABBV) Stock for 2023? | There have been some bright spots among healthcare stocks this year, particularly among the larger-cap equities. The Large Cap-Pharmaceuticals Industry is currently in the top 34% of over 250 Zacks Industries.
The collective total return for the industry is +15% with AbbVie ABBV and Eli Lilly LLY being two of the top p... |
2022-12-16 00:00:00+00:00 | ABBV | AbCellera (ABCL) to Develop New Antibody Therapies With AbbVie | AbCellera Biologics Inc. ABCL announced that it entered a multi-target strategic collaboration with pharma giant AbbVie ABBV to develop new antibody therapies.
Per the agreement, AbCellera is eligible to receive research payments, as well as certain milestone payments and royalties on net sales, if a product is commerc... |
2022-12-16 00:00:00+00:00 | ABBV | Why Pfizer Stock Is Riskier Than AbbVie | What in the world are investors thinking? AbbVie's (NYSE: ABBV) share price has soared more than 20% in 2022. But in a matter of weeks, the company's top-selling drug, Humira, faces competition from biosimilars in the U.S. market.
Meanwhile, Pfizer (NYSE: PFE) stock is down year to date, even though the drugmaker is on... |
2022-12-16 00:00:00+00:00 | ABBV | 2 Dividend Stocks That Could Double Your Return in 10 Years | Pfizer (NYSE: PFE) and AbbVie (NYSE: ABBV) have produced strong total returns over the past decade, and both pharmaceutical companies have what it takes to keep up the pace going forward, despite looming patent cliffs for both.
Over the past five years, AbbVie's total return is 249%, and Pfizer's is 167%, and given the... |
2022-12-16 00:00:00+00:00 | ABBV | AbbVie Submits SNDA For Linaclotide For Treatment Of Children, Adolescents | (RTTNews) - AbbVie (ABBV) has submitted a supplemental New Drug Application for linaclotide or LINZESS to the FDA for the treatment of children and adolescents 6 to 17 years of age with functional constipation. The sNDA submission is based on results from a Phase 3 clinical trial. The company noted that, if approved, l... |
2022-12-15 00:00:00+00:00 | ABBV | AbbVie to leave leading U.S. drug industry trade group | Dec 15 (Reuters) - AbbVie Inc ABBV.N is leaving Pharmaceutical Research and Manufacturers of America (PhRMA), the leading U.S. drug industry group said on Thursday.
Politico, which first reported on AbbVie's exit, said the drugmaker was also leaving the industry group Biotechnology Innovation Organization as well as Bu... |
2022-12-14 00:00:00+00:00 | ABBV | AbbVie (ABBV) Gains As Market Dips: What You Should Know | AbbVie (ABBV) closed the most recent trading day at $164.86, moving +0.04% from the previous trading session. The stock outpaced the S&P 500's daily loss of 0.61%. Meanwhile, the Dow lost 0.42%, and the Nasdaq, a tech-heavy index, added 0.17%.
Prior to today's trading, shares of the drugmaker had gained 7.68% over the ... |
2022-12-13 00:00:00+00:00 | ABBV | Reliable Passive Income: an Analysis on Dividend Kings | In this video, Motley Fool Contributor, Mark Roussin, analyzes all 47 Dividend King stocks. These companies are a great way to diversify your portfolio with a proven track record for dividend payments.
Dividend Kings include the likes of Johnson & Johnson (NYSE: JNJ), Coca-Cola Co (NYSE: KO), Procter & Gamble (NYSE: PG... |
2022-12-10 00:00:00+00:00 | ABBV | AbbVie Presents Data For Navitoclax Combination For JAK Inhibitor-Naïve Myelofibrosis Patients | (RTTNews) - AbbVie (ABBV) said the exploratory analysis from Cohort 3 of the Phase 2 REFINE study of investigational navitoclax in combination with ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis suggested that the combination led to reductions in bone marrow fibrosis (BMF) and variant allele frequency (... |
2022-12-10 00:00:00+00:00 | ABBV | 2 Ultra-Reliable Dividend Stocks You Can Buy Now and Hold Forever | Investors who want to put their money to work for them in the stock market are justifiably nervous about buying shares of anything lately. The benchmark S&P 500 index that tracks the largest publicly traded businesses is down a frightening 17% from the peak it reached in January. The Nasdaq Composite index, which track... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.